Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases

Inhibition of RIPK1 targets 2 major pathogenic events in LP and CLE: epidermal cell death and type 1-mediated skin inflammation.

Authors

Sophia Wasserer
Felix Lauffer (ORCID: https://orcid.org/0000-0002-1992-2836)
Eckart Bartnik
Joachim Saas
Nils Kurzen (ORCID: https://orcid.org/0000-0001-7939-3983)
Stefanie Eyerich (ORCID: https://orcid.org/0000-0002-1166-2355)
Tilo Biedermann (ORCID: https://orcid.org/0000-0002-5352-5105)
Manja Jargosch (ORCID: https://orcid.org/0000-0001-6051-4036)
Theresa Raunegger
Peter Florian
Jessica Eigemann
Carsten B. Schmidt-Weber
Kilian Eyerich
Matthias Herrmann
Danping Ding-Pfennigdorff

Institutions

Boehringer Ingelheim (Germany) (DE)
University of Freiburg (DE)
University Medical Center Freiburg (DE)
Sanofi (France) (FR)
Helmholtz Zentrum München (DE)
LMU Klinikum (DE)
Technical University of Munich (DE)
Ludwig-Maximilians-Universität München (DE)

Publication Details

Journal: Journal of Allergy and Clinical Immunology
Published: 2026-02-01
DOI: https://doi.org/10.1016/j.jaci.2026.02.006
Primary Topic: Cell death mechanisms and regulation
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases

Sophia Wasserer, Felix Lauffer, Eckart Bartnik, Joachim Saas et al.

Feb 1, 2026

Journal of Allergy and Clinical Immunology

Cell death mechanisms and regulation

article

Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases

Sophia Wasserer, Felix Lauffer, Eckart Bartnik, Joachim Saas, Nils Kurzen, Stefanie Eyerich, Tilo Biedermann, Manja Jargosch, Theresa Raunegger, Peter Florian, Jessica Eigemann, Carsten B. Schmidt-Weber, Kilian Eyerich, Matthias Herrmann, Danping Ding-Pfennigdorff

February 1, 2026article en

Abstract

Inhibition of RIPK1 targets 2 major pathogenic events in LP and CLE: epidermal cell death and type 1-mediated skin inflammation.

Journal of Allergy and Clinical Immunology

Boehringer Ingelheim (Germany) (DE), University of Freiburg (DE), University Medical Center Freiburg (DE), Sanofi (France) (FR), Helmholtz Zentrum München (DE), LMU Klinikum (DE), Technical University of Munich (DE), Ludwig-Maximilians-Universität München (DE)

Good health and well-being

Openalex Percentile: Top 53%

Cell death mechanisms and regulation

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1–mediated chronic inflammatory skin diseases — Sophia Wasserer, Felix Lauffer, et al. · Journal of Allergy and Clinical Immunology (2026) | TGRS Research Map | TGRS